The U.S. Food and Drug Administration recently approved the drug Provenge.
"The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available," Karen Midthun, M.D., FDA Center for Biologics Evaluation and Research director, stated in an FDA news release.
According to USA Today, the $93,000 drug doesn't prevent cancer, nor cure it.
"But studies show that (Provenge) does help men with advanced prostate cancer live four months longer than men given placebo shots," Philip Kantoff of the Dana-Farber Cancer Institute, and investigator of a Provenge study, told USA Today.
To learn more about the cancer featured in this post, please visit our prostate cancer information page.